Literature DB >> 18671775

Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome.

J Zeng1, Y-Q Li, X-L Zuo, Y-B Zhen, J Yang, C-H Liu.   

Abstract

BACKGROUND: The intestinal permeability is increased in patients with diarrhoea-predominant irritable bowel syndrome (D-IBS). AIM: To determine the possible efficacy of lactic acid bacteria on the increased intestinal permeability in D-IBS.
METHODS: Treatment was employed for 4 weeks in a randomized single blind placebo controlled study with 30 D-IBS patients. Patients were given either probiotic fermented milk (Streptococcus thermophilus, Lactobacillus bulgaricus, Lactobacillus acidophilus and Bifidobacterium Longum) or milk beverage containing no bacteria. The clinical symptoms were scored and intestinal permeability was measured by a triple sugar test before and after treatment.
RESULTS: Small bowel permeability was measured as the ratio of lactulose and mannitol recovery and colonic permeability was measured as the total mass of sucralose excretion (mg). After probiotics treatment, small bowel permeability decreased significantly from 0.038 (0.024) at baseline to 0.023 (0.020) (P = 0.004), the proportion of patients with increased small bowel permeability was lower than baseline (28.6% vs. 64.3%, P = 0.023). However, colonic permeability improved neither in the probiotics group nor in the placebo group at week 4. Treatment with probiotics significantly decreased the mean global IBS scores compared with the baseline scores (9.62 +/- 1.05 vs. 7.64 +/- 1.24, P < 0.001).
CONCLUSION: Short-term active lactic acid bacteria treatment for D-IBS improved mucosal barrier function.

Entities:  

Mesh:

Year:  2008        PMID: 18671775     DOI: 10.1111/j.1365-2036.2008.03818.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  56 in total

Review 1.  New therapeutic perspectives in irritable bowel syndrome: Targeting low-grade inflammation, immuno-neuroendocrine axis, motility, secretion and beyond.

Authors:  Emanuele Sinagra; Gaetano Cristian Morreale; Ghazaleh Mohammadian; Giorgio Fusco; Valentina Guarnotta; Giovanni Tomasello; Francesco Cappello; Francesca Rossi; Georgios Amvrosiadis; Dario Raimondo
Journal:  World J Gastroenterol       Date:  2017-09-28       Impact factor: 5.742

Review 2.  Gut microbiota role in irritable bowel syndrome: New therapeutic strategies.

Authors:  Eleonora Distrutti; Lorenzo Monaldi; Patrizia Ricci; Stefano Fiorucci
Journal:  World J Gastroenterol       Date:  2016-02-21       Impact factor: 5.742

3.  How can probiotics and prebiotics impact mucosal immunity?

Authors:  Sarah O'Flaherty; Delphine M Saulnier; Bruno Pot; James Versalovic
Journal:  Gut Microbes       Date:  2010-07-07

Review 4.  A review of the pharmacobiotic regulation of gastrointestinal inflammation by probiotics, commensal bacteria and prebiotics.

Authors:  L Vitetta; D Briskey; E Hayes; C Shing; J Peake
Journal:  Inflammopharmacology       Date:  2012-03-18       Impact factor: 4.473

5.  Gut bacteria in health and disease.

Authors:  Eamonn M M Quigley
Journal:  Gastroenterol Hepatol (N Y)       Date:  2013-09

Review 6.  Modulation of microbiota as treatment for intestinal inflammatory disorders: An uptodate.

Authors:  Antonella Gallo; Giovanna Passaro; Antonio Gasbarrini; Raffaele Landolfi; Massimo Montalto
Journal:  World J Gastroenterol       Date:  2016-08-28       Impact factor: 5.742

Review 7.  Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis.

Authors:  Tina Didari; Shilan Mozaffari; Shekoufeh Nikfar; Mohammad Abdollahi
Journal:  World J Gastroenterol       Date:  2015-03-14       Impact factor: 5.742

Review 8.  Probiotics: progress toward novel therapies for intestinal diseases.

Authors:  Fang Yan; David Brent Polk
Journal:  Curr Opin Gastroenterol       Date:  2010-03       Impact factor: 3.287

Review 9.  The role of intestinal microbiota in the development and severity of chemotherapy-induced mucositis.

Authors:  Michel J van Vliet; Hermie J M Harmsen; Eveline S J M de Bont; Wim J E Tissing
Journal:  PLoS Pathog       Date:  2010-05-27       Impact factor: 6.823

Review 10.  The intestinal microbiome, probiotics and prebiotics in neurogastroenterology.

Authors:  Delphine M Saulnier; Yehuda Ringel; Melvin B Heyman; Jane A Foster; Premysl Bercik; Robert J Shulman; James Versalovic; Elena F Verdu; Ted G Dinan; Gail Hecht; Francisco Guarner
Journal:  Gut Microbes       Date:  2012-11-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.